Lisa Dodd

If autonomous vehicles save ~30,000-35,000 lives in the US and ~1.2-1.5 million lives globally, their impact will be unequivocally positive. That said, as measured by GDP, the impact will be a little more nuanced. On the negative side of the GDP ledger, autonomous electric passenger cars probably will lead to fewer accidents,[3] which, while good for passengers and drivers, could hurt economic activity.

The trend toward digital consumption is accelerating. Our analysis suggests that consumers will continue to shift their leisure time from offline to online activities, increasing total online waking hours from ~39% today to 53% in 2030. As a result, adjusted for inflation, global digital leisure spending is likely to increase 17% at a compound annual rate from $6.6 trillion last year to $22.5 trillion in 2030, fueled by five consumer trends.

While not a main driver of our long-term forecast, the Oncomap franchise has synergies with the rest of Exact’s portfolio. Ultimately, some patients using Exact’s MRD service will relapse or advance, necessitating therapy selection testing. Conclusion Exact Sciences is a clear leader in the nascent molecular oncology testing landscape, with Cologuard and Oncotype DX offering durable sources of gross profit that can fund pipeline assets, debt repayment, and the maintenance of infrastructure.